Branch retinal vein occlusion, commonly abbreviated BRVO, is a blockage of one of the smaller veins that drain blood from the retina. It is the most common type of retinal vein occlusion and affects an estimated 23 million people worldwide, making it a leading vascular cause of vision loss after diabetic eye disease.1PubMed Central. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors Most people experience it as a sudden, painless blurring or blind spot in one eye, and while many eyes recover useful vision on their own, the condition can lead to persistent swelling in the central retina that requires ongoing treatment.
What Happens Inside the Eye
The retina’s blood supply involves arteries bringing oxygen-rich blood in and veins carrying spent blood out. In many places throughout the retina, an artery and a vein cross over each other, sharing a thin outer tissue layer called the adventitial sheath. BRVO occurs at one of these crossing points. When the artery stiffens, which happens with aging and cardiovascular disease, it presses down on the softer vein beneath it. That compression narrows or closes the vein’s channel, slowing or stopping blood flow out of the section of retina the vein serves.2PubMed Central. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities
The mechanics can be thought of like stepping on a garden hose. The artery is the foot, the vein is the hose, and the internal limiting membrane of the retina acts like a hard floor underneath. Arterial wall stiffening reduces the give at the crossing site, and the vein gets squeezed between the rigid artery above and the membrane below. The shorter the distance between two arteriovenous crossings, the greater the mechanical compression and the higher the risk.3Journal of Retina. Branch Retinal Vein Occlusion with Arteriovenous Crossing Once the vein is blocked, blood backs up in that section of retina. Pressure rises inside the small capillaries, they leak fluid and blood into the surrounding tissue, and the retina swells. If the blockage is severe enough, some capillaries shut down entirely, starving patches of retina of oxygen.
Who Is at Risk
High blood pressure is the single strongest systemic risk factor. A meta-analysis of published clinical data found that people with hypertension had roughly three times the odds of developing BRVO compared with those without it. High cholesterol carried about twice the odds. Diabetes, somewhat surprisingly, showed only a modest and statistically uncertain association in that same analysis.4PubMed Central. Risk Factors for Central and Branch Retinal Vein Occlusion: A Meta-Analysis of Published Clinical Data A large case-control study confirmed hypertension and peripheral artery disease as significant independent predictors, but also found that diabetes carried meaningful risk on an individual level. That study went further, showing that people diagnosed with BRVO were at higher risk of developing heart failure and stroke in the years afterward, suggesting the eye event can be an early warning sign of broader cardiovascular trouble.5BMJ. Comorbidity in patients with branch retinal vein occlusion: case-control study
Age is a major factor. BRVO prevalence climbs steeply from the 40s onward, peaking in the 60s and 70s. The largest published dataset on BRVO demographics found that about two-thirds of cases present in the sixth and seventh decades of life, with a slight male predominance and more cases in urban populations.6IHOPE Journal of Ophthalmology. Clinical and demographic profile, systemic risk factors, and visual prognosis in branch retinal vein occlusion: Analysis of big data study Glaucoma and ocular hypertension also raise risk, likely because elevated eye pressure adds further stress to retinal veins that are already being compressed at arteriovenous crossing points.
Because BRVO is so tightly linked to cardiovascular health, an eye doctor who diagnoses it will typically refer you for blood pressure and cholesterol screening if those haven’t been checked recently. In younger patients with no obvious cardiovascular risk, additional blood tests for clotting disorders or inflammatory conditions may be warranted.
How BRVO Differs From CRVO
BRVO blocks one branch of the retinal venous system, so the damage is confined to one sector of the retina, usually a quarter or half. Central retinal vein occlusion, or CRVO, blocks the main trunk vein where it exits the eye, affecting the entire retina at once. BRVO is four to six times more common than CRVO.7PubMed Central. Risk Factors for Central and Branch Retinal Vein Occlusion: A Meta-Analysis of Published Clinical Data Because BRVO affects a smaller territory, its natural course tends to be more favorable: collateral veins can reroute blood around the blockage over weeks to months, something that is harder to accomplish when the central vein itself is closed. Still, both conditions share the same core complication, which is swelling in the macula that degrades central vision.
Symptoms and What the Doctor Sees
The hallmark symptom is sudden, painless vision loss or a visual field defect in one eye. The specifics depend on where the blockage sits. If the affected branch vein drains the macula directly (called a macular BRVO), you notice blurriness or distortion right in the center of your vision. If a larger, more peripheral branch is involved (a major BRVO), you may notice a blind spot off to one side while central acuity stays relatively intact.8EyeWiki. Branch Retinal Vein Occlusion Some people with mild peripheral BRVO don’t notice anything at all and are diagnosed incidentally during a routine eye exam.
On examination, a fresh BRVO has a characteristic look. The retinal specialist sees flame-shaped hemorrhages fanning out along the blocked vein, small dot and blot hemorrhages deeper in the retina, cotton-wool spots where nerve fibers have lost their blood supply, and dilated, tortuous veins in the affected sector. Over time, if the blockage persists, the acute hemorrhages fade and are replaced by collateral vessels that form to bypass the obstruction, along with sheathing of the affected vein.9Retina. BRANCH RETINAL VEIN OCCLUSION: Epidemiology, Pathogenesis, Risk Factors, Clinical Features, Diagnosis, and Complications. An Update of the Literature
Getting a Diagnosis
The clinical picture on a dilated eye exam is usually enough to identify BRVO, but imaging is essential for guiding treatment. Two tools dominate. Optical coherence tomography (OCT) gives a cross-sectional view of the macula, revealing fluid accumulation, retinal thickening, and structural damage at a microscopic level. Fluorescein angiography (FA) involves injecting a yellow dye into a vein in the arm and photographing it as it flows through the retinal circulation. FA maps out areas where capillaries have shut down (ischemia) and shows leaking vessels. In one study, peripheral ischemia was found in about 60% of eyes with retinal vein occlusion, and in a fifth of those cases, the ischemia was invisible in the central retina and only revealed by wide-field angiography that captured the periphery.10PubMed Central. Wide-Field Fluorescein Angiography in the Diagnosis and Management of Retinal Vein Occlusion: A Retrospective Single-Center Study This matters because peripheral ischemia can change the treatment plan.
A newer, dye-free alternative called OCT angiography (OCTA) builds a map of blood flow by detecting the movement of red blood cells through the retinal layers. OCTA is better at measuring the fine details of capillary dropout near the macula, while traditional FA still has the edge for seeing what is happening further out in the periphery.11PubMed. Differential microvascular assessment of retinal vein occlusion with coherence tomography angiography and fluorescein angiography: a blinded comparative study In practice, most retina specialists use OCT at every visit and add FA or OCTA when they need a more detailed vascular map. Research has shown that areas of capillary dropout detected by OCTA correspond closely to the blind spots patients report on visual field testing, confirming that these imaging measurements reflect real functional losses.12PubMed Central. Optical coherence tomography angiography and Humphrey field analyser for macular capillary non-perfusion evaluation in branch retinal vein occlusion
The Central Problem With Macular Edema
The most common reason BRVO causes lasting vision loss is macular edema, the swelling of the macula caused by fluid leaking out of damaged capillaries. This swelling is driven in large part by vascular endothelial growth factor (VEGF), a signaling protein that the oxygen-starved retina pumps out in response to the blockage. VEGF makes blood vessel walls more permeable, letting fluid seep into the retinal tissue.13PubMed Central. Cytokines and the Pathogenesis of Macular Edema in Branch Retinal Vein Occlusion
But VEGF isn’t the whole story. A wave of inflammatory molecules floods the affected area too. Studies measuring the fluid inside the eye have found markedly elevated levels of multiple inflammatory cytokines in BRVO eyes, and these levels correlate with how thick the macula is and how poor vision is at the time of measurement.14JAMA Ophthalmology. Association of Inflammatory Factors With Macular Edema in Branch Retinal Vein Occlusion Among these inflammatory markers, one called IL-8 consistently showed the strongest association with vision loss, retinal thickness, and areas of capillary shutdown, suggesting it plays a particularly important role in driving the disease.15Investigative Ophthalmology & Visual Science. Multivariate Analyses of Inflammatory Cytokines in Eyes with Branch Retinal Vein Occlusion: Relationships to Bevacizumab Treatment This mixed VEGF-plus-inflammation picture helps explain why some patients respond brilliantly to anti-VEGF treatment while others keep having the swelling come back.
Treatment Options
Anti-VEGF injections are the current first-line treatment for macular edema caused by BRVO. A Cochrane systematic review of multiple randomized trials concluded that anti-VEGF drugs provide the best outcomes for both visual acuity and macular thickness compared with sham injections, laser treatment, or steroid injections. They are also safer than intravitreal steroids, which carry a higher risk of elevated eye pressure and cataract formation.16Cochrane Database of Systematic Reviews. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion In practice, treatment involves injecting a tiny amount of medication directly into the eye, typically once a month initially and then at gradually longer intervals as the swelling stabilizes.
Steroid implants remain an option, particularly for patients who don’t respond well to anti-VEGF therapy or who have difficulty keeping up with frequent injection visits. A dexamethasone implant can control swelling for two to three months per injection, reducing the total number of visits. Head-to-head trials comparing ranibizumab (an anti-VEGF drug) with a dexamethasone implant found similar visual and anatomic outcomes at one year, but the steroid group had more cases of elevated eye pressure and cataract progression.17PubMed. Comparing ranibizumab, dexamethasone implant, and combined therapy for macular edema secondary to branch retinal vein occlusion: a clinical trial That trade-off between convenience and side effects is a real decision point.
Laser photocoagulation, once the standard treatment, now occupies a narrower role. The landmark Branch Vein Occlusion Study showed that grid laser to the macula could improve vision, and that scatter laser could cut the risk of neovascularization from roughly 22% to 12% and vitreous hemorrhage from 60% to 30% in eyes with significant ischemia.18PubMed Central. Branch Retinal Vein Occlusion Subsequent smaller trials were less convincing about the macular laser benefit.19PubMed. Interventions for branch retinal vein occlusion: an evidence-based systematic review Today, laser is used mainly to treat areas of ischemia where abnormal new vessels might grow, rather than as a primary treatment for macular swelling.
Whether the BRVO is classified as ischemic or nonischemic doesn’t seem to dramatically change how well anti-VEGF therapy works. One study found no significant difference in the number of injections needed or in final vision and macular thickness between ischemic and nonischemic groups, provided the ischemic eyes received early scatter laser to the areas of capillary dropout.20PubMed. Comparison of anti-VEGF results between non-ischemic branch retinal vein occlusion and ischemic branch retinal vein occlusion with early sector panretinal photocoagulation
What Happens Without Treatment
BRVO has a more hopeful natural history than many people expect. A study tracking untreated eyes found that among those with major BRVO, about three-quarters maintained or improved their vision if they started at a moderate level, and roughly two-thirds improved even when starting with poor vision. For macular BRVO, the numbers were even better: about 86% of eyes with decent starting vision held steady or got better on their own.21JAMA Ophthalmology. Branch Retinal Vein Occlusion: Natural History of Visual Outcome A systematic review of the natural history literature confirmed that vision generally improves over the first one to two years, though few untreated eyes recovered better than moderate acuity.22PubMed. Natural history of branch retinal vein occlusion: an evidence-based systematic review
This favorable natural trajectory is one reason BRVO treatment decisions require nuance. For a patient with mild macular edema and still-good acuity, observation with close monitoring may be reasonable. For someone with thick, persistent edema and significant vision loss, early anti-VEGF treatment offers the best chance of recovering and keeping good vision. The trend in clinical practice has shifted strongly toward treating sooner rather than waiting, but knowing that BRVO isn’t automatically a disaster without treatment helps frame realistic expectations.
The Practical Burden of Repeated Injections
Even when anti-VEGF therapy works well, the treatment schedule weighs on patients. A study surveying people receiving intravitreal injections for retinal vein occlusion found that each appointment took an average of four and a half hours including travel, and over a six-month stretch the cumulative time burden was about 13.5 hours. More than half of working patients had to take at least a day off for each appointment. About seven in ten needed someone to accompany them. And three-quarters reported anxiety about the injection itself, with more than half saying the anxiety started at least two days beforehand.23PubMed Central. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion When patients were asked what they wanted most from their treatment, the top answer was fewer injections and fewer visits while keeping the same visual results.
This burden matters clinically, not just personally. Patients who find the schedule too demanding may skip appointments, and gaps in treatment can allow macular edema to return, sometimes permanently damaging vision. Strategies to reduce injection frequency, such as treat-and-extend protocols (where the interval between injections is gradually lengthened as long as the eye stays dry) or switching to longer-acting drugs, are a major focus of current clinical practice.
Surgical Approaches
For years, surgeons have explored the idea of physically relieving the compression at the arteriovenous crossing point. A procedure called arteriovenous sheathotomy involves performing a vitrectomy (removing the gel from inside the eye) and then using a tiny blade to cut through the tissue sheath binding the artery and vein together at the crossing site. A matched-control study found that eyes undergoing sheathotomy had significantly better visual outcomes than eyes managed with observation or laser alone.24PubMed. Sheathotomy to decompress branch retinal vein occlusion: a matched control study In practice, though, this surgery has not caught on widely. It is technically demanding, carries the risks inherent in any vitrectomy, and is hard to justify now that anti-VEGF injections offer strong results without opening the eye surgically. It tends to be reserved for cases where standard medical treatment has failed.
Blood Thinners and BRVO
Because BRVO involves a blocked vein, patients sometimes wonder whether blood-thinning medications would help, either to prevent it or to treat it. The evidence is not encouraging. A study looking at BRVO patients who were already taking antiplatelet or anticoagulant drugs for other reasons found that these medications were actually associated with more macular swelling and more hemorrhage at the time of diagnosis. By the end of follow-up, though, the final visual and structural outcomes were no different from patients not on blood thinners.25PubMed Central. Systemic antiplatelet agents and anticoagulants in eyes with branch retinal vein occlusion The takeaway is that blood thinners do not appear to help the eye recover and may make the initial presentation look worse. They should not be started for the BRVO itself, though of course patients should continue them if they are needed for cardiovascular reasons.
Newer Drug Therapies on the Horizon
The anti-VEGF drugs currently in widespread use for BRVO, including ranibizumab, aflibercept, and bevacizumab, all work by blocking VEGF alone. A newer drug called faricimab targets both VEGF and a second pathway involving a molecule called angiopoietin-2 that contributes to vascular instability and inflammation. Phase III trials called BALATON and COMINO have been evaluating faricimab against aflibercept in patients with macular edema from retinal vein occlusion. The study design includes a treat-and-extend regimen allowing faricimab dosing to stretch out to as long as every 16 weeks.26PubMed Central. BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion Study Design and Rationale If those longer intervals hold up, a drug that needs injection only a few times a year instead of monthly would meaningfully lighten the treatment burden that patients cite as their biggest frustration.
Beyond faricimab, research interest is growing in therapies that address the inflammatory side of BRVO macular edema more directly. Given the evidence that cytokines beyond VEGF drive swelling in at least a subset of patients, combination approaches or drugs targeting additional inflammatory pathways could help the group who don’t respond fully to anti-VEGF alone. None of these are in routine clinical use yet, but they represent a recognition that the one-size-fits-all anti-VEGF model leaves room for improvement.
BRVO as a Cardiovascular Warning
One aspect of BRVO that doesn’t get enough attention is what it signals about the rest of the body. The same arterial stiffening that squeezes a retinal vein is happening in blood vessels elsewhere. The case-control study described earlier found that after a BRVO diagnosis, patients faced elevated rates of new hypertension diagnoses, diabetes, heart failure, and cerebrovascular disease in subsequent years.27BMJ. Comorbidity in patients with branch retinal vein occlusion: case-control study In other words, the eye event may be the first visible consequence of systemic vascular disease that has been building silently.
For this reason, a BRVO diagnosis should prompt not just eye treatment but a thorough cardiovascular workup if you haven’t had one. Getting blood pressure and cholesterol under control won’t reopen the blocked retinal vein, but it can reduce the chance of a second occlusion in the same or the fellow eye, and more importantly, lower the risk of heart attack and stroke. The retina is the one place in the body where doctors can directly see blood vessels without cutting anything open. When those vessels show damage, it’s worth taking the hint.